Meds & supplements › Tenofovir disoproxil
Medicine
Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor and an HBV reverse transcriptase inhibitor.
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued emtricitabine and tenofovir disoproxil fumarate. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue emtricitabine and tenofovir disoproxil fumarate. If appropriate, anti-hepatitis B therapy may be warranted. Emtricitabine and tenofovir disoproxil fumarate used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of emtricitabine and tenofovir disoproxil fumarate for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed. WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued emtricitabine and tenofovir disoproxil fumarate tablets. Hepatic function should be monitored closely in these individuals who discontinue emtricitabine and tenofovir disoproxil fumarate tablets. Emtricitabine and tenofovir disoproxil fumarate tablets used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with the use of emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP if signs or symptoms of acute HIV infection are present unless negative infection status is confirmed.
Emtricitabine and tenofovir disoproxil fumarate tablet is a prescription medicine that is used.
Emtricitabine and tenofovir disoproxil fumarate tablets contains the prescription medicines emtricitabine and tenofovir disoproxil fumarate.
It is not known if emtricitabine and tenofovir disoproxil fumarate tablets for treatment of HIV-1 infection is safe and effective in children who weigh less than 37 pounds (17 kg).
It is not known if emtricitabine and tenofovir disoproxil fumarate is safe and effective in reducing the risk of HIV-1 infection in people who weigh less than 77 pounds (less than 35 kg).
For people taking Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP:
Do not take Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP if:
Emtricitabine and tenofovir disoproxil fumarate tablets can only help reduce your risk of getting HIV-1 before you are infected.
Emtricitabine and tenofovir disoproxil fumarate, can cause serious side effects, including:
For more information about side effects, see the section "What are the possible side effects of emtricitabine and tenofovir disoproxil fumarate tablets?".
Other important information for people who take emtricitabine and tenofovir disoproxil fumarate tablets to help reduce their risk of getting human immunodeficiency virus-1 (HIV-1) infection, also called pre-exposure prophylaxis or "PrEP":
Before taking emtricitabine and tenofovir disoproxil fumarate tablets to reduce your risk of getting HIV-1:
While you are taking emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP:
If you have HIV-1 and take only emtricitabine and tenofovir disoproxil fumarate tablets, over time your HIV-1 may become harder to treat.
Emtricitabine and tenofovir disoproxil fumarate tablets may cause serious side effects, including:
The most common side effects of emtricitabine and tenofovir disoproxil fumarate tablets for treatment of HIV-1include:
Common side effects in people who take emtricitabine and tenofovir disoproxil fumarate for HIV-1 PrEP include:
These are not all the possible side effects of emtricitabine and tenofovir disoproxil fumarate tablets.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Emtricitabine and tenofovir disoproxil fumarate tablets, t ell your healthcare provider about all of your medical conditions, including if you:
Pregnancy Registry: There is a pregnancy registry for people who take Emtricitabine and tenofovir disoproxil fumarate tablets during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about how you can take part in this registry.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Some medicines may interact with emtricitabine and tenofovir disoproxil fumarate. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
Keep emtricitabine and tenofovir disoproxil fumarate tablets and all other medicines out of reach of children.
General information about Emtricitabine and tenofovir disoproxil fumarate tablets:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use emtricitabine and tenofovir disoproxil fumarate tablets for a condition for which it was not prescribed. Do not give emtricitabine and tenofovir disoproxil fumarate tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about emtricitabine and tenofovir disoproxil fumarate tablets that is written for health professionals.
sofidex [Internet]. Daloreum; c2026. Tenofovir disoproxil; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/tenofovir-disoproxil
sofidex. (2026, August 2). Tenofovir disoproxil. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/tenofovir-disoproxil
Tenofovir disoproxil. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/tenofovir-disoproxil
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.